Ensysce Biosciences, Inc. (ENSC)
Largest Insider Buys in Sector
ENSC Stock Price History Chart
ENSC Stock Performance
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Insider Activity of Ensysce Biosciences, Inc.
Over the last 12 months, insiders at Ensysce Biosciences, Inc. have bought $0 and sold $0 worth of Ensysce Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Ensysce Biosciences, Inc. have bought $370,327 and sold $8.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 90,287 shares for transaction amount of $44,087 was made by GOWER BOB G (director) on 2023‑03‑02.
List of Insider Buy and Sell Transactions, Ensysce Biosciences, Inc.
| 2023-03-02 | director | 90,287 0.6576% | $0.49 | $44,087 | -71.07% | |||
| 2023-03-01 | director | 270,000 2.1241% | $0.48 | $128,979 | -68.06% | |||
| 2023-02-28 | director | 109,300 0.8628% | $0.49 | $53,371 | -68.47% | |||
| 2022-12-09 | director | 357,143 19.2974% | $1.40 | $500,000 | -83.82% | |||
| 2022-05-25 | Chief Executive Officer | 27,000 0.0797% | $0.53 | $14,216 | -78.38% | |||
| 2020-06-19 | Sale | 10 percent owner | 776,290 0.2223% | $10.44 | $8.1M | -4.82% | ||
| 2017-12-01 | 10 percent owner | 1M 4.2688% | $10.00 | $10M | +28324.91% |
Insider Historical Profitability
| HG Vora Capital Management, LLC | 10 percent owner | 3837500 294.0771% | $5.65 | 1 | 0 | |
| GOWER BOB G | director | 1222682 93.6971% | $5.65 | 4 | 0 | <0.0001% |
| Kirkpatrick Lynn | Chief Executive Officer | 381851 29.2622% | $5.65 | 1 | 0 | |
| MORGAN STANLEY | 10 percent owner | 0 0% | $5.65 | 0 | 1 |